Sep 2026· Cancer Treatment Reviews· Vol 150, pp.
103212
· 0 citations· 88 references
Medicine
TL;DR
The biological function of p53, its role in EGFR-mutant lung cancer, and the implications for current and future therapies are discussed, and a timely and cohesive synthesis of a rapidly evolving field is offered.
Abstract
Non-small cell lung cancer (NSCLC) harbouring mutations in the epidermal growth factor receptor (EGFR) represents a well-defined molecular subset that is amenable to targeted therapies. However, clinical heterogeneity in treatment response and resistance highlights the critical need for a deeper understanding of co-occurring genetic alterations. Among these, TP53 mutations are the most frequent co-mutations observed in EGFR-mutant NSCLC and are increasingly recognized for their prognostic and predictive relevance. With the emergence of next-generation sequencing in routine diagnostics and the growing arsenal of targeted therapies, the time is ripe to comprehensively assess how p53 co-mutations shape tumor biology, influence drug resistance, and impact patient outcomes. This review integrates recent mechanistic insights with therapeutic strategies and emerging clinical data, offering a timely and cohesive synthesis of a rapidly evolving field. The biological function of p53, its role in EGFR-mutant lung cancer, and the implications for current and future therapies are discussed.
EGFR-TKIs have significantly improved the survival outcomes of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, substantial heterogeneity in treatment efficacy exists among individuals, and conventional single-gene testing has limitations in guiding therapeutic decision-making. This systematic rev...
Yun Feng· Theoretical and Natural Scie...· 0 citations
Triple-negative breast cancer (TNBC) remains a highly aggressive and therapeutically challenging subtype, defined by the absence of oestrogen, progesterone, and HER2 expression. Tumour Protein 53 (TP53) mutations represent the most frequent genetic alteration, occurring in over 80% of cases and driving tumour initiatio...
B. Karikalan, Ye Htut Linn, Shiueh-Lian Mok· Bulletin du Cancer· 0 citations
KRAS biology, therapeutic advances, mechanisms of resistance, and emerging strategies that are reshaping the treatment landscape of KRAS-mutant NSCLC are comprehensively summarized.
E. Garbo, P. Scaparone, H. J. Hoe et al.· The Journal of the National...· 0 citations
Background Treatment of non-small cell lung cancer (NSCLC) has evolved dramatically over the past decade with the advent of widespread genetic testing, immunotherapy, and targeted therapies. Treatments directed against epidermal growth factor receptor (EGFR) and other driver mutations have reduced toxicity and improved...
Aaron Negin, Kush Sachdeva, J. Weiss· Frontiers in Oncology· 0 citations
The complexity of KRAS biology in NSCLC is highlighted and the importance of integrating molecular, epigenetic, and therapeutic insights to advance precision medicine and improve clinical outcomes is underscored.
Jadwiga Gaździcka, K. Gołąbek· International Journal of Mol...· 0 citations
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have substantially improved outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC), but acquired resistance remains a major barrier to durable disease control.
Objective: This narrative review summarizes the major...
Kai Yan, Ke-Wei Tian, Lai-Ling Du et al.· Eurasian Journal of Medicine...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.